Citigroup
ORIC icon

Citigroup’s Oric Pharmaceuticals ORIC Stock Holding History

Citigroup’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-28,700
Closed -$703K – 6325
2021
Q1 		$703K Buy
+28,700
New +$907K ﹤0.01% 3225

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citigroup's ORIC Position: Q2 2026 in Review

Citigroup increased its Oric Pharmaceuticals (ORIC) stake by 1,364% in Q2 2026, buying an estimated $2.1M and bringing the position to 248,757 shares worth $2.69M. The position accounts for ﹤0.01% of the portfolio, ranked #2697.

Citigroup first reported a position in ORIC in Q2 2020 and has held it in 24 quarters since. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Citigroup held 248,757 shares of Oric Pharmaceuticals worth $2.69M as of Q2 2026.
  • Citigroup bought 231,763 Oric Pharmaceuticals shares in Q2 2026, an estimated $2.1M.
  • Oric Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2697 holding.
  • Citigroup first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.